ZESTORETIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zestoretic, and when can generic versions of Zestoretic launch?
Zestoretic is a drug marketed by Almatica and is included in one NDA.
The generic ingredient in ZESTORETIC is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZESTORETIC?
- What are the global sales for ZESTORETIC?
- What is Average Wholesale Price for ZESTORETIC?
Summary for ZESTORETIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 3 |
Patent Applications: | 120 |
Drug Prices: | Drug price information for ZESTORETIC |
What excipients (inactive ingredients) are in ZESTORETIC? | ZESTORETIC excipients list |
DailyMed Link: | ZESTORETIC at DailyMed |
Recent Clinical Trials for ZESTORETIC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre Hospitalier Universitaire de Saint Etienne | Phase 4 |
IPCA Laboratories Ltd. | Phase 1 |
Pharmacology for ZESTORETIC
Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for ZESTORETIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-001 | Sep 20, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-002 | Jul 20, 1989 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZESTORETIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-001 | Sep 20, 1990 | ⤷ Sign Up | ⤷ Sign Up |
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | ⤷ Sign Up | ⤷ Sign Up |
Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-002 | Jul 20, 1989 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZESTORETIC
See the table below for patents covering ZESTORETIC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 8106134 | ⤷ Sign Up | |
Netherlands | 930007 | ⤷ Sign Up | |
South Korea | 840005083 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZESTORETIC
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0480717 | 98C0025 | Belgium | ⤷ Sign Up | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0443983 | C00443983/03 | Switzerland | ⤷ Sign Up | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |